XML 28 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows used in operating activities:    
Net loss $ (160,055) $ (3,450)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,067 145
Stock-based compensation expense 140,667 196
Change in fair value of warrant derivative liability 1,366 16
Change in value of note payable   377
Forgiveness of note receivable from related party   115
Bad debt expense   32
Loss incurred by Inex Bio 57  
Gain on settlement of note payable (133)  
Changes in operating assets and liabilities, net of effects of acquisition:    
Accounts receivable 75 151
Prepaid expenses and other current assets (1,584) 68
Other assets (1,161) (19)
Accounts payable 3,815 (449)
Accrued expenses 820 126
Due to related parties 610  
Deferred rent 342  
Deferred revenue (106) (106)
Net cash used in operating activities (14,220) (2,798)
Cash flows used in investing activities:    
Purchases of property and equipment (1,286) (198)
Purchase of Inex Bio Inc., net of cash acquired (1,818)  
Investment in intangible assets (141) (53)
Net cash used in investing activities (3,245) (251)
Cash flows provided by financing activities:    
Proceeds from equity offerings, net of issuance costs 316,189 5,781
Payments on notes payable (132) (52)
Proceeds from exercise of Class B common stock   69
Proceeds from exercise of warrants 7,340  
Repurchase of common stock (4,798)  
Employee payroll taxes paid related to net share settlement of restricted stock units (2,415)  
Proceeds from exercise of stock options 843 80
Net cash provided by financing activities 317,027 5,878
Effect of exchange rate changes on cash and cash equivalents (50)  
Net increase in cash and cash equivalents 299,512 2,829
Cash and cash equivalents, beginning of period 59,104 350
Cash and cash equivalents, end of period 358,616 3,179
Cash paid during the period for:    
Income taxes 6 1
Interest   52
Supplemental disclosure of non-cash investing and financing activities:    
Conversion of debt and payables into common stock   1,339
Conversion of debt into Preferred Series C stock   1,000
Change in par value from $0.001 to $0.0001   $ 1
Cashless exercise of warrants 1,773  
Other Owner Of Inex Bio Inc    
Supplemental disclosure of non-cash investing and financing activities:    
Issuance of warrants in Inex Bio, Inc. acquisition $ 5,170